CSE1L

Exportin-2 · P55060 · CSE1L on Sugi Atlas →

0 patent compounds predicted against CSE1L, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to CSE1L by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma PHASE2RECRUITING
Selinexor, High-dose Methotrexate, and Rituximab Combined With Radiotherapy for Newly Diagnosed, Transplant-ineligible Patients With Central Nervous System Lymphoma: An Open-label, Single-arm, Multicenter Phase II Study PHASE2RECRUITING
Selinexor, Cyclophosphamide and Prednisone in Myeloma PHASE2COMPLETED
Selinexor With ICE Chemotherapy in Secondary Central Nervous System Involving B-cell Non-Hodgkin Lymphoma PHASE1/PHASE2RECRUITING
Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) PHASE2ACTIVE_NOT_RECRUITING
Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers PHASE1/PHASE2RECRUITING
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS PHASE2COMPLETED
A Trial of Selinexor, Ruxolitinib and Methylprednisolone PHASE1RECRUITING
A Study of Drug Therapies for Salivary Gland Cancers Based on Testing of Genes nanCOMPLETED
Immunophenotyping and Xist Gene in AML nanUNKNOWN
A Clinical Study on the Efficacy and Safety of Methotrexate (MTX) or Thiotepa (for MTX Intolerance) or Temozolomide (TMZ) Combined With Orelabrutinib and Selinexor in Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma(SELINA) nanRECRUITING
A Study of the Interaction Between Tumor Susceptibility Gene Glycine N-methyltransferase (GNMT) and Lung Cancer nanUNKNOWN
Selinexor (Nexpovio®) (SVd) in Patients With Relapsed or Refractory Multiple Myeloma nanACTIVE_NOT_RECRUITING
MEHMO Natural History and Biomarkers nanRECRUITING
Prevalence of a Non-Expressing 11B Mutation in Aka Peoples of the Central African Republic nanCOMPLETED
Maternal Genes and Epimutations: Beckwith-Wiedemann Syndrome & Reproductive Risks nanRECRUITING
Aberrant Splicings Due to Microsatellite Instability in Colorectal Cancer : Physiopathological and Clinical Impact nanUNKNOWN
Novel Biomarkers in the Neoplastic Progression of Barrett's Esophagus nanACTIVE_NOT_RECRUITING
Genetic Susceptibility in MAlignant Pleural Mesothelioma: Clinical Implication of GermliNE variaTionS nanRECRUITING
Target of Suv420h1/2 in Hepatocytes nanRECRUITING
SMN Circular RNAs as Potential Biomarkers for the Therapeutic Response to Nusinersen in Spinal Muscular Atrophy Patients nanUNKNOWN
Treatment of Chronic Lymphocytic Leukemia nanUNKNOWN
Assessment Of Long Noncoding RNA CCAT1 In Colorectal Cancer Patients nanUNKNOWN
Novel Strategy for Early Detection of Esophageal Squamous Cell Carcinoma nanRECRUITING
Role of SF3B1 Mutation in Assessment of Acute and Chronic Lymphatic Leukemia nanNOT_YET_RECRUITING
Whole-genome Sequencing Study in Patients With Diminished Ovarian Reserve nanUNKNOWN
Characterization of Methylation Pattern in Human Germ Cells of Patients Undergoing ICSI Treatment nanCOMPLETED
Thermogenic Silencer Regulatory Factors in Humans nanACTIVE_NOT_RECRUITING
Evaluation of CEMIP in Pancreatic Cancer nanUNKNOWN
Human MATER and Idiopathic Infertility nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a CSE1L binder may also engage these)

ProteinNameSimilarity
Q8AY73 1.000 Q8AY73 →
Q5R9J2 1.000 Q5R9J2 →
A5D785 1.000 A5D785 →
Q9ERK4 1.000 Q9ERK4 →
Q6GMY9 1.000 Q6GMY9 →
Q9PTU3 1.000 Q9PTU3 →
Q7SZC2 1.000 Q7SZC2 →
Q9XZU1 0.999 Q9XZU1 →
O13671 0.995 O13671 →
Q9ZPY7 0.993 Q9ZPY7 →
Q06142 0.992 Q06142 →
P14068 0.992 P14068 →
P30822 0.990 P30822 →
O13864 0.988 O13864 →
IPO11 Importin-11 0.988 landscape →
Q2U3V3 0.987 Q2U3V3 →
O14089 0.987 O14089 →
P33307 0.987 P33307 →
O59809 0.986 O59809 →
Q569Z2 0.986 Q569Z2 →
Q91YE6 0.986 Q91YE6 →
Q704U0 0.986 Q704U0 →
Q9EPK7 0.986 Q9EPK7 →
Q8K2V6 0.985 Q8K2V6 →
A6RVT8 0.985 A6RVT8 →
IPO9 Importin-9 0.985 landscape →
Q8H0U4 0.984 Q8H0U4 →
Q5R9G4 0.984 Q5R9G4 →
A1DEK2 0.984 A1DEK2 →
Q5ZLT0 0.984 Q5ZLT0 →